Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of Carfilzomib and Melphalan and Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL)

NCT01842308 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01842308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01842308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of Carfilzomib and Melphalan and Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL)
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Completed
Start date
June 4, 2013
Completion date
October 28, 2019
Enrollment
50 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ds stage i plasma cell myeloma, ds stage ii plasma cell myeloma, ds stage iii plasma cell myeloma, refractory plasma cell myeloma